Spinal Muscular Atrophy Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Spinal Muscular Atrophy is a genetic neuromuscular disease which is characterized by muscle atrophy and weakness. This disease generally manifests in early ages and may leads to the genetic cause of death in toddlers and infants. SMA is caused due to the defects in Survival Motor Neuron 1 (SMN1) gene which encodes the SMN protein. The SMN protein plays a vital role in health and survival of nerve cells in spinal cord responsible for muscle contraction (motor neurons).
Symptoms of SMA includes weak arms and legs, movement problems, tremors, swallowing problems, difficulty in breathing, problems in joints and bones.Spinal Muscular Atrophy is diagnosed by molecular genetic testing, electromyogram, CT Scan, MRI, Muscle tissue biopsy.Â Spirinza (Nusinersen) is the only FDA approved drug to treat SMA. Spirinza was approved in 2016 by U.S. FDA.
By Trial Phase, Spinal Muscular Atrophy pipeline drugs are segmented as:
By Company, Spinal Muscular Atrophy pipeline drugs are segmented as:
By Drugs, Spinal Muscular Atrophy pipeline drugs are segmented as:
By Mechanism of Action, Spinal Muscular Atrophy pipeline drugs are segmented as:
By Types of Spinal Muscular Atrophy diseases, Spinal Muscular Atrophy pipeline drugs are segmented as:
By Route of Administration, Spinal Muscular Atrophy pipeline drugs are segmented as:
Spinal Muscular Atrophy Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Spinal Muscular Atrophy treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Spinal Muscular Atrophy disease pipeline drugs development. This report studies the dynamics of the Spinal Muscular Atrophy Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Spinal Muscular Atrophy disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.